Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDY-5301 for ICU Acquired Weakness in Trauma
NCT04430283Phase 2Terminated
- Sponsor
- Faraday Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Sodium iodide in intensive care unit-acquired weakness (ICU-AW), sponsored by Faraday Pharmaceuticals. Started Sep 2021; status: terminated.
02
Drugs
Sodium iodide
03
Conditions
intensive care unit-acquired weakness (ICU-AW)
Beyond the preview
Go deeper on NCT04430283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430283.